French AFU Cancer Committee Guidelines – Update 2026–2028: Penile cancer - 20/11/26
, Agate Escoffier a, c, Annabelle Goujon a, d, Laurence Rocher a, e, f, Aude Fléchon a, g, Nicolas Branger a, h, Philippe Camparo a, i, Stephan Levy a, j, Pierre-Henri Savoie a, k, Thibaut Murez a, l, Morgan Roupret a, mAbstract |
Objective |
To update the French guidelines of the Cancer Committee of the French Association of Urology on the epidemiology, prevention, diagnosis, treatment, and follow-up of penile tumors for the 2026–2028 period.
Materials and methods |
A comprehensive review of the literature published since the previous update, up to 2026, was performed. Recent international classifications and guidelines were incorporated. The available literature was assessed according to its level of evidence to formulate recommendations applicable to clinical practice.
Results |
Squamous cell carcinomas account for 95% of invasive penile cancers. Two carcinogenic pathways are recognized, HPV dependent and HPV independent, the latter being notably associated with lichen sclerosus and chronic inflammation. Prevention is based on HPV vaccination, patient information regarding risk factors, and the management of chronic inflammatory conditions. Any persistent penile lesion should prompt biopsy without delay. Clinical examination remains essential for local staging and may be supplemented by magnetic resonance imaging when an organ-preserving strategy is considered. Treatment should favor organ preservation whenever oncologically feasible, with negative surgical margins being mandatory. Lymph node assessment is a major prognostic determinant. In clinically node-negative patients with intermediate- or high-risk tumors, bilateral sentinel lymph node biopsy is recommended. In clinically node-positive patients, 18-FDG PET contributes to staging, although histological confirmation remains necessary. Radical inguinal lymph node dissection is indicated in patients with proven nodal involvement. For cN3 disease, neoadjuvant chemotherapy is recommended, followed by surgery in responders. In the metastatic setting, chemotherapy remains the standard treatment. Data concerning immunotherapy are encouraging but remain insufficient to support its use outside clinical trials. Intensive follow-up should be performed during the first 2 years and should include local and inguinal examinations, patient self-examination, quality-of-life assessments, and psychosexual support.
Conclusion |
The management of penile cancer relies on early diagnosis, organ preservation whenever feasible, and prompt risk-adapted lymph node management. Centralization of care within expert multidisciplinary teams is essential for optimizing oncological, functional, and psychosexual outcomes.
Le texte complet de cet article est disponible en PDF.Keywords : Penile cancer, Squamous cell carcinoma, Human papillomavirus, Sentinel lymph node, Inguinal lymph node dissection, Guidelines
Plan
Vol 36 - N° 11
Article 103197- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
